**Core Concept**
The question is testing knowledge of emetogenic potential of anticancer (anti-CA) drugs, which is a critical factor in managing chemotherapy-induced nausea and vomiting.

**Why the Correct Answer is Right**
The correct answer is a highly emetogenic anti-CA drug, which means it has a high potential to cause nausea and vomiting. This is due to its mechanism of action, which involves disrupting cell division and causing DNA damage. The drug's emetogenic potential is partly attributed to its ability to stimulate the release of serotonin from the enterochromaffin cells in the gastrointestinal tract, leading to activation of the vagus nerve and subsequent vomiting. The drug's high emetogenic potential requires the use of antiemetic prophylaxis to prevent chemotherapy-induced nausea and vomiting.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because the drug has a moderate emetogenic potential, not high. It is still used in chemotherapy regimens but requires less aggressive antiemetic prophylaxis.
**Option B:** This option is incorrect because the drug has a low emetogenic potential, making it a good choice for patients who are at risk of severe chemotherapy-induced nausea and vomiting.
**Option C:** This option is incorrect because the drug is not commonly used in chemotherapy regimens and has a different mechanism of action that does not involve high emetogenic potential.

**Clinical Pearl / High-Yield Fact**
It's essential to assess the emetogenic potential of anti-CA drugs in patients undergoing chemotherapy to determine the appropriate antiemetic prophylaxis strategy. The World Health Organization (WHO) has a classification system for emetogenic potential, which can guide treatment decisions.

**Correct Answer:** C. Dacarbazine is a highly emetogenic anti-cancer drug.